上海医药:2026年第一季度公司药品CSO业务新承接7个品种的商业化合作

证券日报
Jul 29

证券日报网7月29日讯 ,上海医药在接受调研时表示,2026年第一季度,公司药品CSO业务,新承接7个品种的商业化合作,产品矩阵持续优化丰富,为后续业绩增长奠定了扎实基础。值得关注的是,4月15日,上药控股与全球制药巨头企业强生达成CNS(中枢神经系统)领域全国全渠道战略合作,获得善思达、善妥达、善久达三款长效针剂独家市场推广权,此次合作标志着公司在精神CNS领域迈入新发展阶段,CSO专业服务能力...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10